Kornimate/medical-research-clean huggingface dataset:
relationship between oral findings and salivary factors in sars-cov-2 patients

Conditions: Decay, Dental; Missing Teeth; COVID-19; Cytokine Storm

Summary: two hundred individuals will be formed according to the study and control groups: group-1: coronavirus 2 (covid-19) (+) patients (n=100) and group-2: healthy individuals (in which the volunteers will be included due to group-1) (n=100). oral examinations including dmft scores, salivary flow rate, visible gingival index scores and radiographs (opg) will be performed on both groups on the 1st appointment. oral swap samples will be collected with sterile swap brushes (six sample for each person) on the 1st, 7th and 30th days to evaluate the salivary immunoglobulins (immunoglobulin a (iga), immunoglobulin g (igg), immunoglobulin m (igm)) and cytokine (il-1, il-6, il-10) levels. blood samples will be collected to validate the oral swap test results.

severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is the virus responsible for coronavirus disease 2019 (covid-19) which also affects all systems of the body including the oral environment. recent studies have demonstrated the association between oral health status and systemic diseases. including systemic infections and respiratory diseases. aim of this study is to analyze the immunoglobulin and cytokine levels of sars-cov-2 patients and correlate the oral health status of these patients. our hypotheses are, 1) covid-19 affects individuals with low oral hygiene (high dmft score) more severely, 2) oral cytokine levels will increase similarly to blood levels in patients with covid-19, 3) oral immunoglobulin levels in patients with covid-19 decreased similarly to those in blood. oral examination of 100 covid (+) patients which were hospitalized due to acute respiratory failure will be performed in the dental department of each faculty hospital. decay-missing-filled tooth (dmft) scores, visible gingival plaque index (löe-silness), bleeding on probing (bop) scores, and orthopantomographs (opg) will be collected for each participant. oral swap specimens will be collected (6 sample for each person) to evaluate the levels of salivary immunoglobulins (iga, igg, igm) and cytokines (il-1, il-6, il-10) on 1st, 7th, and 30th days. elisa test will be performed for immunological analysis with ready-made kits (sunred biotech. co, shanghai, china). full blood analyses will be performed to validate and correlate the actual cytokine and immunoglobulin levels.

Eligibility criteria:
inclusion criteria: * covid (+) patients, * patients who were hospitalized due to acute respiratory deficiency, * conscious patients in icu (intensive care unit) or idmc (infectious diseases and microbiology clinic). exclusion criteria: * patients with cancer, * patients with autoimmune system diseases, * pregnant women, * patients with immune deficiency diseases (acquired immune deficiency syndrome - aids, autoimmune lymphoproliferative syndrome - alps , chronic granulomatous disease - cgd, etc.).
gulf, lantus, apidra evaluation in type 1 diabetics study

Conditions: Diabetes Mellitus, Type 1

Summary: primary objective : to evaluate the efficacy (in terms of change in hba1c readings starting from baseline then after 13 weeks \& at the end of the study which will be after 26 weeks) in subjects with type i diabetes mellitus. secondary objective : * recording the average daily dose of both insulin glulisine \& insulin glargine in type i dm. * recording adverse events.


Eligibility criteria:
inclusion criteria: * newly diagnosed type i diabetic patients * type i diabetes treated with basal-bolus regimen including 3 or more injections of regular human insulin per day * bmi, 26-40 kg/m2 * hba1c, 7.5%-10% * median 2hrs post -prandial more than or equal to 140 mg/dl (more than or equal to 7.8 mmol/l) * fpg more than or equal to 120 mg/dl (more than or equal to 6.7 mmol/l) * willingness to accept, and ability to inject insulin glargine therapy exclusion criteria: * pregnancy : the use of lantus \& apidra during pregnancy is not contraindicated. however, in the absence of supportive data, sanofi- aventis pharmaceuticals cannot specifically recommend the use of lantus in this patient population the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
laparoscopic bursectomy and d2 lymphadenectomy vs.laparoscopic d2 lymphadenectomy in advanced gastric cancer

Conditions: Gastric Cancer Stage II; Gastric Cancer Stage III

Summary: to investigate the clinical efficacy and safety of laparoscopic bursectomy and d2 lymphadenectomy (lbdl group) versus laparoscopic d2 lymphadenectomy (ldl group) in advanced gastric cancer by prospective randomized controlled clinical trial.

to compare the lbdl group and ldl group in the advanced gastric cancer. a prospective randomized controlled trial will be performed in the gi department, guangdong provincial hospital of chinese medicine from november 2016 to november 2024. the sample size，100 cases with advanced gastric cancer, will be needed after calculated by the statistics. the 100 cases will be randomly divided into two groups: lbdl group and ldl group. primary outcomes are the 3 years' disease-free survival (dfs) rate, the secondary outcomes are the 3 years' and 5 years' disease-free survival (dfs) rate, the 3 years and 5 years overall survival（os）rate, operative time, the total blood loss, the intra-operative complication and the post-operative complication, the number of lymph nodes dissected, the number of conversion to open laparotomy, and the other outcomes are the average time of ground activities, the hospital stay. the data in two groups will be compared.

Eligibility criteria:
inclusion criteria: 1. the age limits is 18-80 years old; 2. t3-t4 resectable gastric carcinoma,confirmed by ct and pathology. 3. the preoperative imaging confirmed that the tumor did not involve adjacent organs; 4. american society of anesthesiologists (asa) score less than or equal to level 3; 5. criteria of performance status karnofsky is greater than or equal to 60. exclusion criteria: 1. the patients' age limits is less than 18 years old, or more than 80 years old; 2. the preoperative imaging confirmed that the tumor involve adjacent organs; 3. the tumor have been finding distant metastases; 4. american society of anesthesiologists (asa) score more than 3; 5. criteria of performance status karnofsky is lower than 60; 6. there is a laparoscopic surgery contraindications.

Keywords: laparoscopic bursectomy d2 lymphadenectomy gastric cancer
effect of high-flow nasal oxygen on extubation outcome

Conditions: Respiratory Failure; Congestive Heart Failure; COPD

Summary: the purpose of this study is to determine whether high flow nasal cannula is effective in lowering the reintubation rate after extubation for high risk patients in medical intensive care unit

the study hypothesis is that optiflow may reduce the extubation failure rate for high risk patients in medical intensive care unit.in the intervention group, patients fulfilling inclusion criteria and not presenting any of the exclusion criteria will receive high-flow nasal cannula (optiflow airvo2, fisher \& paykel healthcare ltd., new zealand) after extubation. the oxygen concentration (fio2) will be set to reach an oxygenation target similar to control patients (see below), while the gas flow rate will be set at 50 l/min.in the control group, patients fulfilling inclusion criteria and not presenting any of the exclusion criteria will receive standard oxygen therapy including nasal cannula or oxygen mask after extubation. the fio2 will be set to obtain a arterial oxygen saturation (spo2) between 92% and 98% (or between 88% and 95% in hypercapnic patients). nippv or intubation will be applied in both group if respiratory distress noted. high flow nasal cannula will be tried before nippv or intubation in the control group patients.

Eligibility criteria:
inclusion criteria: * patients mechanically ventilated for \> 48 hours and at least one of the following: * \> 65 y/o * cardiac failure as the primary indication of mechanical ventilation * copd * bronchiectasis * old pulmonary tuberculosis with destructive lung * chronic renal failure * neuromuscular disease * bmi \> 30 * inability to manage respiratory secretions * ards exclusion criteria: * presence of tracheostomy * recent facial trauma * active gastro-intestinal bleeding * planned nippv support after extubation

Keywords: high flow nasal cannula extubation failure
a russian prospective observational study of invasive fungal infections in patients with acute leukemia and hematopoietic stem cell transplantation

Conditions: Invasive Fungal Infections

Summary: estimate the rate of occurrence of invasive fungal infections (ifis) in patients with acute leukemia for the first 6 months of chemotherapy (that usually correspond to four courses of chemotherapy), and hematopoietic stem cells transplantation.

this multi-center observational study of ifi in high risk hematological patients, the study will investigate the epidemiology of ifi, describe antifungal strategy, proportion of antifungal prophylaxis, empiric therapy, pre-emptive therapy and targeted therapy in at-risk patients.

Eligibility criteria:
inclusion criteria: * diagnosed with de novo or relapsed al (aml, all)started chemotherapy * all newly allogeneic or autologous transplant recipients during the study period

Keywords: invasive fungal infection acute leukemia (al) hematopoietic stem cell transplantation antifungal stewardship neutropenia hematological malignancies
the significance of ambrosia in allergic rhinitis and asthma in israel

Conditions: Allergic Rhinitis; Asthma; Allergic Conjunctivitis; Atopic Dermatitis

Summary: ambrosia is known for its allergenicity in the usa causing hay fever and asthma. israel has always been considered "clean" of ambrosia but over the past years growth of ambrosia plants has been detected in several locations in israel. in the proposed study, patients referred for routine allergic evaluation will also be skin tested with ambrosia allergens, in addition to their regular prick skin tests with all other airborne allergens.


Eligibility criteria:
inclusion criteria: * patients with allergic rhinitis, asthma, allergic conjunctivitis or atopic dermatitis who undergo prick skin tests with airborne allergens
evaluation of a portable device for assessing sleep disordered breathing in congestive heart failure

Conditions: Heart Failure, Congestive; Sleep Apnea Syndromes

Summary: the purpose of this study is to evaluate an approved, portable device for assessing sleep disordered breathing in congestive heart failure.


Eligibility criteria:
inclusion criteria: * moderate to severe heart failure (as determined via echocardiogram or treating physician) exclusion criteria: * clinically significant asthma requiring therapy * significant (parenchymal) lung disease * severe pulmonary hypertension * hypercapnia (pco2 \> 60mmhg) * cardiogenic shock * severe chronic renal failure * narcotic abuse/intravenous drug use (including heart failure due to alcohol abuse or chemotherapy, hiv+ and hepatitis c) * methicillin- resistant staphylococcus aureus infection * tracheotomy * enrolled in any concurrent study that may confound the results of this study * nocturnal positive airway pressure or oxygen * inability or refusal to sign patient consent form * inability or refusal to adhere to protocol requirements
axonics sacral neuromodulation system for urinary urgency incontinence treatment

Conditions: Urinary Incontinence, Urge

Summary: the artisan-snm study is designed to evaluate the safety and effectiveness of the axonics sacral neuromodulation system as an aid in the treatment of the symptoms of urinary urgency incontinence (uui) in patients who have failed or could not tolerate more conservative treatments.

the artisan-snm trial which was a single-arm, prospective study that included 29 centers and enrolled 129 participants. the primary aim of the study was to evaluate the safety and efficacy of the axonics snm system for the treatment of uui symptoms. primary outcome was improvement in uui episodes on a 3-day bladder diary. secondary outcomes included quality of life using the iciq-oabqol questionnaire, patient satisfaction, and bowel symptoms captured using the cleveland clinic florida fecal incontinence score (ccf-fis). participants were followed out to 2 years and data was reported at 6 months, 1 year and 2 years

Eligibility criteria:
primary inclusion criteria: 1. diagnosis of uui demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, at least 50% of all leaking episodes associated with urgency, and at least one leaking episode each 24-hour period. 2. greater than or equal to 6 months' history of uui diagnosis 3. for male subjects only: peak flow rate \> 15 cc/s as verified by uroflowmetry within 6 months prior to enrollment; residual bladder volume \< 150 cc tested within 6 months prior to enrollment 4. 21 years of age and older 5. willing and capable of providing informed consent 6. capable of participating in all testing associated with this clinical investigation primary exclusion criteria: 1. stress incontinence or mixed incontinence. 2. current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 3. interstitial cystitis or bladder pain syndrome as defined by either american urological association (aua) or european association of urology (eau) guidelines 4. a female who is breastfeeding 5. a female with a positive urine pregnancy test

Keywords: sacral neuromodulation (snm) snm
rivastigmine in mild alzheimer's disease, fmri study

Conditions: Alzheimer' Disease

Summary: the purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fmri response during a face recognition task. furthermore, the aim is to investigate whether fmri response is correlated with long term treatment effect at 6 months and 12 months.


Eligibility criteria:
inclusion criteria: * probable alzheimer's disease according to the nincds-adrda criteria * mild disease, cdr 1 * the clinician is planning to start anticholinesterase treatment exclusion criteria: * cognitive impairment for other reason than alzheimer's disease * severe depression * other unstable physical disease * medal in body prevention mri examination, claustrophobia * cardiac pacemaker * other significant neurologic or psychiatric disease * contraindication for anticholinesterase treatment

Keywords: alzheimer's disease fmri face recognition rivastigmine
alcohol addiction and otorhinolaryngology cancer

Conditions: Cancer of the Upper Aero-digestive Tract; Alcoholism

Summary: the aim of the study is to compare the hospitalisation period in orl surgery for two groups of patients. one of them will be treated for alcohol addiction to weaning them before the surgery orl. the other group will be treated with usual methods.

alcohol, associated or not associated with tobacco, is known to increase the incidence of orl cancer. so, in fact many patients perform their orl surgery operation in spite of their alcohol addiction. many studies showed that a post surgery weaning syndrome increases morbidity and mortality. so our study will focuses on the benefits of pre surgery medical weaning program. the protocol is an open randomised, prospective study. the patient will be divided in two groups. in one hand, the first group is designed as "treated" will get alcohol weaning in the hospital alcohol department. the patient will be hospitalized during one week before the orl surgery. during this hospitalisation, the patient will receive medicinal treatment, medical follow-up and psychological counselling. in the other hand, the second group designed as "control group" will be hospitalized directly in orl surgery department. the patient will be received a treatment for alcohol weaning according to their symptom. after their hospitalisation, the treated group will be followed-up regularly for their alcohol addiction either in support group or in individual counselling. the control group will be followed-up with the usual method in the orl surgery department. the expected result is to improve the care for patients with alcohol addiction and who must have an orl surgery reducing the hospitalisation duration, the level of post operative complication and increasing the abstinence level. 115 patients will be included in this study.

Eligibility criteria:
inclusion criteria: * age 18-80 years, male or female * clinically and histologically verified orl cancer required surgery * patient with alcohol addiction * men must consume 21 glasses of wine a week * women must consume 14 glasses of wine a week * cpam affiliation * able to give written informed consent to participate in the study exclusion criteria: * inability to give informed consent * patient with regulatory authority or private patient freedom

Keywords: alcohol addiction
central and peripheral 24-h blood pressure before and after 3 month of cpap treatment in obstructive sleep apnea

Conditions: Chronic Kidney Disease; Obstructive Sleep Apnea

Summary: the purpose of this study is to investigate the effect of 3 months of continuous positive airway pressure (cpap) treatment of obstructive sleep apnea (osa) in moderate to severe cases in patients with chronic kidney disease. the effect is evaluated on blood pressure levels, particularly nocturnal blood pressure, both central and peripheral, and renal function, including the kidneys treatment of salt and water. hypothesis: 1. central 24-h blood pressure measuring is a reveals fluctuations in blood pressure during the day more accurately than peripheral 24-h blood pressure measuring because the measurement is painless and does not interfere with the patient activities during the daytime or nighttime sleep. 2. central blood pressure is elevated in patients with osa and falls during treatment with cpap. 3. the renal tubular function relating to the treatment of water and sodium is abnormal in patients with osa with increased tubular absorption of water via the u-aquaporin 2 (u-aqp2) and of sodium by epithelial sodium channel (enac) and is normalized during treatment with cpap. 4 quality of life is improved during treatment with cpap.

approximately 30 patients with chronic kidney disease and obstructive sleep apnea in moderate to severe degree is examined with central and peripheral 24-h blood pressure monitoring, 1 night home polygraphy to determine the degree of sleep apnea, blood and urine samples to determine levels of u-aqp2, u-enac, plasma renin concentration (prc), s-angiotensin ii (p-angii), p-aldosterone, p-vasopressin (p-avp) and p-endothelin, before the start treatment with cpap for sleep apnea. after 3 month of treatment all the above described is repeated to determine effects of cpap treatment on blood pressure levels during the day, changes i apnea hypopnea index (ahi) and the kidneys treatment of salt and water.

Eligibility criteria:
inclusion criteria: * renal insufficiency (ckd stage iii + iv), estimated glomerular filtration rate (egfr) 15-59 ml/min/1.73 m2 * obstructive sleep apnea, ahi\> 15 (moderate to severe) * both men and women * 18-80 years exclusion criteria: * lack of desire to participate * malignant disease * abuse of drugs or alcohol * pregnant and lactating * incompensated heart failure * atrial fibrillation * liver disease (alanine aminotransferase\> 200) * severe chronic obstructive lung disease (forced expiratory volume in 1 second \<50% predicted)

Keywords: chronic kidney disease obstructive sleep apnea 24-h blood pressure central blood pressure peripheral blood pressure
perioperative chemotherapy after primary chemotherapy for locally advanced breast cancer

Conditions: Breast Neoplasms; Carcinoma

Summary: the role of early timing of adjuvant chemotherapy was postulated to be particularly important for patients with endocrine non-responsive disease. the role of cytotoxicity during the period of breast surgery itself and immediately after (perioperative chemotherapy) remained unknown. we investigated in a randomized trial the role of perioperative chemotherapy in patients treated with a preoperative chemotherapy for locally advanced breast cancer and compare it to the preoperative chemotherapy without additional cytotoxic therapy during and immediately after definitive surgery. patients with t2-3 n0-2 m0 breast cancer, with both estrogen receptors (er) and progesterone receptors (pgr) expressed in less than 20% of tumor cells, or with absence of progesterone receptors, received up to 6 courses of primary systemic therapy with epirubicin 25 mg/m2 intravenously (i.v.) on days 1 and 2, cisplatin 60 mg/m2 i.v. on day 1, and 5-fluorouracil 200 mg/m2 i.v. daily as continuous infusion (ecf). patients achieving a partial or complete remission were randomized to continue the infusion of fluorouracil until 2 weeks after surgery (perioperative treatment arm) or to stop fluorouracil infusion one week before surgery, on day 21 of the sixth cycle (control arm).


Eligibility criteria:
inclusion criteria: * patients with breast cancer histologically proven \> 2 cm, er and pgr \<20% or any er and pgr absent (t2,t3 n0-2, m0) * no treatment with previous chemotherapy/hormonotherapy * performance status 0-2 (ecog scale, appendix 2) * measurable or evaluable lesions * age between 18-70 years * no significant intercurrent illness such as diabetes, cardiovascular, renal or neurologic impairments * absence of psychiatric illness * wbc \> 4,000/mm3; plts \> 100,000/mm3 * ast, alt, ldh, gamma-gt \< 2.5 x upper limit of normal and bilirubin \< 3 mg/100 ml * informed consent obtained * pregnancy test (in fertile women). an effective contraceptive method must be utilized by fertile women. * baseline examinations (chest x ray, ct scan, ecg etc) performed within one month prior initiation to therapy exclusion criteria: * uncontrolled infection and metabolite disease * distant metastases * active peripheric and/or central neurological disease * active cardiac disease defined as chf (nyha iii-iv) significant arrhytmias, bilateral bundle branch block or recent (less than 3 months) history of myocardial infarction * history of second malignancy (exception in situ carcinoma of the uterine cervix and basal or squamous cell carcinoma of the skin)

Keywords: antineoplastic protocols neoadjuvant therapy perioperative chemotherapy fluorouracil